Scilex Holding Company (SCLX) Insider Trading Activity

NASDAQ$1.82-0.03 (-1.62%)
Market Cap
$13.01M
Sector
Healthcare
Industry
Drug Manufacturers—General
Rank in Sector
758 of 849
Rank in Industry
14 of 14

SCLX Insider Trading Activity

SCLX Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
–
Sells
$0
0
–

Related Transactions

About Scilex Holding Company

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid …

Insider Activity of Scilex Holding Company

Over the last 12 months, insiders at Scilex Holding Company have bought $0 and sold $0 worth of Scilex Holding Company stock.

On average, over the past 5 years, insiders at Scilex Holding Company have bought $178,164 and sold $600.69M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 30,000 shares for transaction amount of $13,800 was made by SHAH JAISIM (See Remarks) on 2024‑12‑18.

List of Insider Buy and Sell Transactions, Scilex Holding Company

2024-12-18PurchaseSHAH JAISIMSee Remarks
30,000
0.016%
$0.46
$13,800
-13.74%
2024-10-31PurchaseJi HenryExecutive Chairperson
8,888
0.0068%
$0.94
$8,351
-58.73%
2024-10-29PurchaseSHAH JAISIMSee Remarks
32,000
0.0257%
$0.99
$31,670
-60.18%
2024-10-18PurchaseChun Jaydirector
5,000
0.0038%
$0.95
$4,750
-58.70%
2024-10-18PurchaseFollowwill Dormandirector
1,000
0.0008%
$0.99
$990
-58.70%
2024-10-17PurchaseJi HenryExecutive Chairperson
10,000
0.0079%
$0.97
$9,710
-57.67%
2024-10-17PurchaseWu Yue Alexanderdirector
20,000
0.0154%
$0.95
$18,992
-57.67%
2024-10-17PurchaseLemus Daviddirector
2,000
0.0015%
$0.90
$1,800
-57.67%
2024-10-16PurchaseSHAH JAISIMSee Remarks
30,000
0.0241%
$0.99
$29,751
-53.43%
2024-10-16PurchaseMa Stephen HoiChief Financial Officer
6,700
0.0053%
$0.97
$6,499
-53.43%
2024-05-17PurchaseSHAH JAISIMSee Remarks
56,939
0.0422%
$0.92
$52,099
-23.65%
2024-05-17PurchaseChun Jaydirector
57,500
0.0418%
$0.90
$51,641
-23.65%
2024-05-17PurchaseJi HenryExecutive Chairperson
50,000
0.0356%
$0.88
$43,985
-23.65%
2024-05-17PurchaseMa Stephen HoiChief Financial Officer
14,140
0.0101%
$0.88
$12,443
-23.65%
2024-05-16PurchaseSHAH JAISIMSee Remarks
83,061
0.0566%
$0.84
$69,846
-17.98%
2023-09-21Sale
Sorrento Therapeutics, Inc.
10 percent owner
60.07M
–
$10.00
$600.69M
-20.00%
Total: 16

Insider Historical Profitability

<0.0001%
Ji HenryExecutive Chairperson
320161
4.5511%
$592,297.8530
<0.0001%
SHAH JAISIMSee Remarks
139333
1.9806%
$257,766.0550
<0.0001%
Chun Jaydirector
112500
1.5992%
$208,125.0020
<0.0001%
Wu Yue Alexanderdirector
25000
0.3554%
$46,250.0010
<0.0001%
Ma Stephen HoiChief Financial Officer
22840
0.3247%
$42,254.0020
<0.0001%
Followwill Dormandirector
2300
0.0327%
$4,255.0010
<0.0001%
Lemus Daviddirector
2000
0.0284%
$3,700.0010
<0.0001%

Historical Insider Profitability vs. Competitors

$1,927,310,793
31
28.02%
$1,325.87B
$364,368,632
29
9.65%
$36.8B
$6,224,380
25
3.58%
$640.75B
$23,541,811
22
6.43%
$126.14B
$28,542,809
19
26.39%
$505.4B

SCLX Institutional Investors: Active Positions

Increased Positions24+23.53%556,657+70.23%
Decreased Positions30-29.41%218,685-27.59%
New Positions12New106,506New
Sold Out Positions15Sold Out178,484Sold Out
Total Postitions96-5.88%1M+42.64%

SCLX Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$3,697.003.53%282,424-11,890-4.04%2025-09-30
Blackrock, Inc.$1,288.001.23%98,382-33,950-25.66%2025-09-30
Geode Capital Management, Llc$970.000.93%74,139+12,300+19.89%2025-09-30
Armistice Capital, Llc$864.000.83%66,000+66,000New2025-09-30
State Street Corp$438.000.42%33,433+21,545+181.23%2025-09-30
Hrt Financial Lp$418.000.4%31,908+31,908New2025-09-30
Ubs Group Ag$336.000.32%25,650+7,224+39.2%2025-09-30
Morgan Stanley$303.000.29%23,156+5,102+28.26%2025-09-30
Renaissance Technologies Llc$251.000.24%19,164+19,164New2025-09-30
Ashton Thomas Private Wealth, Llc$235.000.23%17,989+17,989New2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.